Patients with relapsed/refractory Hodgkin lymphoma (RR-HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents have impacted prognosis in general population of patients with RR-HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR-HL with relapse post-ASCT.
| I N T R O D U C T I O N
Classical Hodgkin lymphoma (HL) is a clonal lymphoid malignancy that occurs at a rate of 2-3 per 100,000 population with an estimated 8500 new cases in the United States in 2016. 1 The majority of patients diagnosed with HL will go on to achieve a durable clinical response with current first or second line therapies and, in fact, nearly 80% of patients will be cured of their disease with standard frontline chemotherapy, radiotherapy, or a combination of these two modalities. The remaining 20% of patients have either primary refractory disease or will go on to relapse following initial therapy. Historically, this group of primary refractory or relapsed HL (RR-HL) patients have had limited treatment options and a poor prognosis.
The current standard of care for patients with RR-HL is salvage chemotherapy followed by autologous stem cell transplantation (ASCT), which results in cure rates of up to 50% and improved outcomes compared to conventional chemotherapy alone. [2] [3] [4] [5] [6] Patients who relapse following ASCT have a poor prognosis; most relapse within one year and have a median overall survival (OS) of 25 months from transplant. [7] [8] [9] [10] [11] Historically, treatment options for these patients have included additional conventional chemotherapy, radiation, repeat ASCT, or reduced-intensity conditioning allogeneic-SCT. Recently, therapeutic options for these patients have expanded with the development of promising targeted therapies, including brentuximab vedotin, an anti-CD30 monoclonal antibody-drug conjugate linked to auristatin, which was approved by the FDA in 2011 and immune check point inhibitors.
Several clinical studies have suggested that patients with RR-HL who are treated with brentuximab experience benefit, with high clinical response rates and improved progression free-survival (PFS). In the pivotal phase 2 study that led to the accelerated FDA approval of brentuximab, the overall response rate was 75% and the median PFS was 6.7 months. For the patients who had attained a complete response, Response to ASCT was defined using the revised response criteria for malignant lymphoma 19 at the initial response assessment following ASCT. Disease progression following ASCT was defined by either radiographic or biopsy evidence of progression, whichever was documented earlier. OS was estimated from the date of post-ASCT relapse or progression to the date of death. Dates of death were verified using medical records and available public records, including the Social Security National Death Index. Patients who were lost to follow-up were censored on the date of their last contact with the health system.
| Statistical analysis
Univariate survival analysis was performed using proportional hazards ratios. Median OS was estimated using the Kaplan-Meier method and the log rank test of the equality of survival functions was used to compare OS between groups. All P-values were two-sided and P .05 was considered statistically significant. Median length of follow-up was estimated using the reverse Kaplan-Meier method. 20 All statistical analyses were carried out using STATA 14.0.
| R E S U L T S 3.1 | Patient characteristics
We identified 87 patients with RR-HL with progression following ASCT (see Table 1 ). The mean age of our patients at initial diagnosis was 35.6 years (range 13.5-74.9). The majority of patients were male (54.5%). Among the classical HL subtypes, nodular sclerosis was the most common (80.7%), followed by mixed cellularity (9.1%). 
| Survival analysis
The median OS from disease progression following ASCT for the entire 
| DISCUSSION
In this retrospective analysis of patients with RR-HL who progressed following ASCT, we found that patients treated with novel therapeutics experienced improved OS compared to patients treated with Although our data demonstrates a median OS of 85 months in patients exposed to at least one novel agent (and longer in those HL has demonstrated 3-year OS of 73%. 24 With 5-year follow-up of this trial, 38% of patients who achieved an initial CR remained in remission at five years and median OS for those with an initial CR had not been reached by the end of the study. 13 Gandolfi and colleagues reported a 63.3% rate of long-term response to brentuximab (defined as >/5 12 months). 25 Our data suggest that outcomes may be even better than those previously reported. The reason for these observed differences may be the result of differences in patient population, duration of therapy, disease characteristics, or clinical response. Forty-five percent of patients (10 of 22) in this study achieved CR to brentuximab, higher than the previously reported CR rate of 34%. 18, 24 This higher CR rate may account for the prolonged OS we observed in our cohort. To address this question, we looked specifically at patients who had a CR to brentuximab compared to those with PR, SD, or PD and found a trend toward improved survival in those with CR ( Figure 2E ), however, the interpretation of this result was significantly limited by sample size (n 5 22).
We also found that patients in our study who experienced CR or PR in response to ASCT had improved median OS compared to patients who experienced SD or PD following transplant. Similarly, patients with "chemosensitive" disease (i.e., experienced CR or PR to first-line therapy) had improved survival compared to those with "chemo-refractory" disease (Table 2 , Figure 2C ,D). The inferior survival in these patient with poor response to front-line therapy and/or ASCT is likely a reflection of a more aggressive disease phenotype, findings which have been reported elsewhere. Moreover, patients who were treated with radiation therapy before transplant were not more likely to be treated with post-ASCT radiotherapy. Those who received radiation therapy post-ASCT were not more likely to have presented with localized or early stage disease upon diagnosis. These data suggest that the survival benefit observed with post-ASCT radiotherapy in our population is unrelated to prior radiation therapy or disease burden at initial diagnosis.
Milgrom and colleagues recently described practice patterns pertaining to radiation therapy in those undergoing ASCT for RR-HL and found that patients treated with radiation therapy in the peritransplant setting were more likely to have early stage disease both at initial diagnosis and upon relapse, although radiation therapy was not associated with improved PFS or OS in that study. 27 One explanation for improved survival in patients treated with post-ASCT radiotherapy in the current study is the presence of more localized disease upon relapse, though this association was not explored specifically in the present study.
Several limitations of this study should be considered. The singlecenter, retrospective nature of this study make it vulnerable to several biases, including patient selection bias and confounding variables.
Because the majority of the patients in the control group were historical controls from the pre-novel agent era, it is possible that practice patterns had changed, resulting in improvement in outcomes, thereby amplifying any difference in median OS. Another limitation is the absence of early prognostic data; many of the patients included in this analysis were referred to our center after failure of initial therapy at other centers. As such, initial prognostic data is lacking for the majority of the cohort, limiting our ability to use this data to further characterize outcomes.
The standard approach to front-line and salvage therapies will continue to evolve rapidly in the coming years. Abbreviations: ASCT, autologous stem cell transplant; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
